References
Baselga J, Tripathy D, Mendelsohn et al.: Phase II study of weekly, intravenous, recombinant, humanized anti-p185 Her-2 monoclonal antibody in patients with Her 2/neu overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744, 1996
Cobleigh MA, Vogel CL, Tripathy D et al.: Multinational study of the efficacy and safety of humanized anti-Her-2 monoclonal antibody in women who have Her-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648, 1999
Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first line treatment of Her-2 overexpressing metastatic breast cancer. J Clin Oncol 120: 719–726, 2002
Carbonell-Castellon X, Casteneda-Soto NJ, Clemens M et al.: Efficacy and safety of 3 weekly Herceptin monotherapy in women with Her-2 positive metastatic breast cancer: preliminary report from a phase II study. Proc Am Soc Clin Oncol 21: 19a, 2002 (abstract 73)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vogel, C. Trastuzumab Monotherapy. Breast Cancer Res Treat 81 (Suppl 1), 67–68 (2003). https://doi.org/10.1023/A:1026325008419
Issue Date:
DOI: https://doi.org/10.1023/A:1026325008419